The Role of the Consciousness Energy Healing Treated Novel Test Formulation on Different Vital Organ Functional Biomarkers

Journal: Global Research Journal of Public Health and Epidemiology  

Published: August 12, 2019 Volume: 6 Issue: 5

ISSN: 2360-7920

Authors: Su-Mei Chen Liu, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal and Snehasis Jana

  • 32 Views
  • 2 Downloads

Abstract

The study objective was to investigate the potential of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs, and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Su-Mei Chen Liu, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of Biofield Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5% (at 0.1 μg/mL), 127.9% (at 10 μg/mL), and 53.3% (at 25 μg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 195%, 242.5%, and 117.5% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 μg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.2% (at 10 μg/mL) in the BT-Med + BT-TI; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 μg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 94.5% (at 0.1 μg/mL) and 77.7% (at 25 μg/mL) in the BT-Med + BT-TI groups, respectively; while 58.4% (at 10 μg/mL) in the BT-Med + BT-TI group compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 70.3% and 106% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively 1 μg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 μg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 58.4% and 135.9% in the BT-Med + BT-TI group at 10 and 25 μg/mL, respectively; while 72.8% (at 25 μg/mL) in the BT-Med + UT-TI group as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 373.2% (at 1 μg/mL) and 263.1% (at 10 μg/mL) in the BT-Med + UT-TI group; while 318.4% (at 1 μg/mL) and 224.4% (at 10 μg/mL) in the BT-Med + BT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The study findings showed that the tested novel test formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. The treatment group like BT-Med + BT-TI showed 53.5%, 127.9%, and 53.3% restoration of cell viability at 0.1, 10, and 25 μg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Additionally, 195%, 242.5%, and 117.5% restoration of cell viability at 0.1 μg/mL in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 94.2% in the BT-Med + BT TI group at 10 μg/mL; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 μg/mL than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 94.5% and 77.7% at 1 and 25 μg/mL, respectively in the BT-Med + BT-TI group compared to the untreated group in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 106% in the BT-Med + BT-TI group 1 μg/mL compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 μg/mL compared to the untreated group in A549 cells. The serotonin level was significantly increased by 135.9% at 25 μg/mL in the BT-Med + UT-TI group as compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 373.2% and 318.4% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 μg/mL compared to the untreated group in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs related functional enzymes and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic etc. to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.